Mitigating inflammation and fibrosis: the therapeutic potential of quercetin liposomes in COPD
Frontiers in Pharmacology · 17.12.2024 · 15
DOI: 10.3389/fphar.2024.1503283 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 17.12.2024. Verfasst von Changfeng Yin und 12 weiteren Autor:innen. Beteiligte Einrichtung: China National Tobacco Quality Supervision & Test Center, Zhengzhou, China. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: COPD
Abstract (Originalsprache)
Introduction
Chronic obstructive pulmonary disease (COPD) is a disease with severe therapeutic obstacles and high worldwide death rate. COPD progresses predominantly through inflammatory response followed by fibrotic destruction. Quercetin (Que), recognized for its anti-inflammatory effects, presents significant promise as a therapeutic candidate for COPD therapy. However, poor water solubility and low bioavailability of Que hinder its further clinical application. Liposomes are renowned for their unique structure and function, which provided an efficient approach for the delivery of Que in various drug delivery systems. This study was aim to prepare a novel Que liposome (Que-lipo) and administrated via intratracheal (i.t.) with cigarette smoke induced COPD mice. The underlying therapeutic mechanisms against lung damage of Que-lipo were explored.
Methods
Que-lipo were prepared based on thin film dispersion method and administrated via intratracheal administration. The cigarette smoke induced COPD mice were established and a comprehensive approach was employed to explore the inflammation, pulmonary function and histopathology of lung after i.t. administration of Que-lipo, including enzyme-linked immunosorbent assay, histopathology and immunohistochemistry, reverse transcription-quantitative polymerase chain reaction. Results and discussion Que-lipo not only improved the solubility and biocompatibility of Que but also demonstrated effective cellular uptake in vitro . The inflammation, pulmonary function and pathological condition of lung were improved after i.t. administration of Que-lipo. Que-lipo also regulated the expression of key apoptosis-associated proteins such as Bcl-2 and caspase-3/7, leading to significant inhibition of apoptotic activity in COPD. Furthermore, Que-lipo markedly enhanced its ability to alleviate lung inflammation and fibrosis symptoms by modulating inflammation-related factors and fibrosis signaling molecules. The potential mechanisms of Que-lipo in treating COPD were elucidated, including the suppression of the NLRP3/IL-1β inflammasome pathway and the TGF-β1-related fibrosis signaling pathway.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- China National Tobacco Quality Supervision & Test Center, Zhengzhou, China.
- Beijing Life Science Academy, Beijing, China.
- Key Laboratory of Tobacco Biological Effects, Zhengzhou, China.
- School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.
Zitieren
APA
Yin, C., Tian, Y., Yan, A., Wang, H., Lu, F., Li, X., Li, X., Han, S., Miao, R., Chen, H., Li, D., Hou, H., & Hu, Q. (2024). Mitigating inflammation and fibrosis: the therapeutic potential of quercetin liposomes in COPD. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1503283
Vancouver
Yin C, Tian Y, Yan A, Wang H, Lu F, Li X, et al. Mitigating inflammation and fibrosis: the therapeutic potential of quercetin liposomes in COPD. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1503283
BibTeX
@article{Yin2024,
author = {Yin, Changfeng and Tian, Yushan and Yan, An and Wang, Hongjuan and Lu, Fengjun and Li, Xianmei and Li, Xiao and Han, Shulei and Miao, Ruijuan and Chen, Huan and Li, Di and Hou, Hongwei and Hu, Qingyuan},
title = {Mitigating inflammation and fibrosis: the therapeutic potential of quercetin liposomes in COPD},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1503283}
}
EUVIMED